课题基金 / 基金详情

NEUROPEPTIDES--MOLECULAR MECHANISM OF ACTION

NEUROPEPTIDES--MOLECULAR MECHANISM OF ACTION
神经肽--分子作用机制
批准号:
6162312
负责人:
L H LAZARUS
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

L H LAZARUS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Summary of Work: Structure-activity studies on d-opioid heptapeptide agonists and selective d-opioid di- and tripeptide antagonists containing Dmt-Tic were modified to enhance membrane permeability. Introduction of Aib in agonists amplified activities and amphiphilicity due to a-helical formation. The antagonists were modified at N- and C-termini with hydrophobic constituents that increased biological stability by eliminating cyclization to a diketopiperazines, nonetheless cyclo(Dmt-Tic) exhibited a unique conformation whose activity was less than linear molecules. N-Alkylation with methyl groups retained high d affinity and selectivity, whereas ethyl, piperidine, pyrrolidine, or pyyrole reduced affinity to the 1-2 nM range and subsequently decreased selectivity. C-Terminal modification (methoxy, hydrazide, methyl amide, adamantanyl amide) reduced d-selectivity by enhancing m-affinity, such that adamantanyl amide resulted in a peptide with high affinity for d- and m-receptors and agonist bioactivities. A complementary system that induces pain (nociception) through a heptadecapeptide represents the natural regulatory system on opioid effects. Structure-activity relationships revealed that nociceptin (1-13) is the minimal bioactive compound and various substitutions affected receptor and bioactivities. Thus, a combination of unique opioid agonists and antagonists, and the heptadecapeptide of the nociceptin system would permit us to better understand treatment of pain and differentiate opioid from antiopioid functions in clinical situations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MOLECULAR DYNAMICS CONFORMATION OF OPIOID PEPTIDES
MOLECULAR DYNAMICS CONFORMATION OF OPIOID PEPTIDES
NEUROREGULATORY ASPECTS OF NEUROMEDIN B
NEUROREGULATORY ASPECTS OF NEUROMEDIN B
海外基金